FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: The School of Pharmacy, University of London (ULSOP)

The University of London, School of Pharmacy (ULSOP) (www.pharmacy.ac.uk) is the only academic institution in the UK entirely devoted to teaching and research in pharmacy and pharmaceutical sciences. It has a research track record of international excellence and attracts post-graduate and post-doctoral researchers from all over the world. The School's Centre for Toxicology has grown into one of the major centres internationally for the study of combination effects, especially of endocrine disrupting chemicals. The ultimate goal of the Centre's research programme is to provide mechanistic understandings of combination effects of xenobiotics. The main tasks of ULSOP are to implement relevant assays in the field of Neurotoxicity (SP2) for multi-component mixture experiments, as well as to have input on the Steering Committee of ESNATS. ULSOP will bring expertise from work with endocrine disrupting chemicals into this area.

Key staff involved in the project

Andreas KortenkampAndreas Kortenkamp, Dr. rer. nat. is involved with several EU-funded projects. He was a partner in the ACE project (www.the-ace-project.info) and is coordinator of the EDEN project (www.edenresearch.info) and the EU endocrine disrupter cluster CREDO (www.credocluster.info). He represented the topic "Endocrine disruption" in the SCALE Technical Working Group "Research needs". The input of his group was instrumental in establishing validated tools for the prediction of combination effects in in vitro EDC mode-of-action screens. Recently, this approach was extended successfully to dealing with in vivo effects of anti-androgens in trans-generational rat studies.

Further information: www.pharmacy.ac.uk

Top ^